A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Nitazoxanide (Primary)
- Indications COVID 2019 infections; Respiratory tract infections; Viral infections
- Focus Registrational; Therapeutic Use
- Sponsors Romark Laboratories
Most Recent Events
- 28 Jun 2022 Status changed from active, no longer recruiting to discontinued.
- 31 Mar 2021 Status changed from recruiting to active, no longer recruiting.
- 05 Feb 2021 Planned End Date changed from 31 Dec 2020 to 30 Jun 2021.